Navigation Links
Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association

this threshold for at least 20 hours per week.

"We are pleased to report strong evidence supporting our hypothesis that administration of a threshold concentration of SNS-595 sustained over a defined period of time results in disease remissions in patients with acute leukemias," said Daniel C. Adelman, M.D., Sunesis' Senior Vice President, Research and Development. "Based on these recent data from our Phase 1 trial, a potential relationship between dose, pharmacodynamic target modulation and clinical response appears to be emerging which should allow us to select doses rationally for our planned Phase 2 clinical studies. With clinical responses observed to date in a study population with relapsed and/or refractory acute leukemias, we expect that SNS-595 will continue to show positive evidence of clinically meaningful activity as we escalate dosing in both treatment schedules to the MTD in this trial."

Dose escalation is in subsequent cohorts is continuing, with a 72 mg/m2 weekly dose cohort and a 50 mg/m2 twice-weekly cohort currently enrolling. Once the maximum tolerated dose (MTD) has been identified in each schedule, the study will enroll up to 10 additional patients at the MTD for each dosing regimen. Sunesis currently anticipates completing the clinical trial in time to report final results at the American Society of Hematology (ASH) meeting in Atlanta in December of this year.

SNS-595 is a replication-dependent DNA damaging agent that causes double- stranded DNA breaks, irreversible G2 arrest, and rapid apoptosis. The ongoing Phase 1 trial is being conducted by leading investigators at the H. Lee Moffitt Cancer Center & Research Institute, Johns Hopkins Hospital and the University of Texas, MD Anderson Cancer Center. The Phase 1 study is designed to assess the safety, tolerability and pharmacokinetics of SNS-595 and to establish a recommended Phase 2 dose for further testing among patients with acute leukemia. In addition, evidence fr
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
2. Sunesis Pharmaceuticals to Present Data at the 12th Congress of the European Hematology Association
3. Sunesis Presents Data Supporting SNS-032s Potential Anticancer Activity in Multiple Myeloma at the American Association for Cancer Research Meeting
4. Sunesis Pharmaceuticals to Present Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
Post Your Comments:
(Date:5/26/2015)... May 26, 2015  Organovo Holdings, Inc. (NYSE MKT: ... breakthrough 3D bioprinting technology, announced today that the company ... 2015 Healthcare Conference, to be held in ... Keith Murphy , Chairman and Chief Executive Officer, ... advances and partnerships. Details of the presentations ...
(Date:5/26/2015)... May 26, 2015  RXi Pharmaceuticals Corporation ... focused on discovering and developing innovative therapies ... ophthalmology, today announced that the Company,s President and ... present at the Jefferies 2015 Global Healthcare ... 11:30 a.m. EDT. Dr. Cauwenbergh will present ...
(Date:5/26/2015)... May 26, 2015 For the ... Quality of Life Throughout Europe, the Middle ... Astellas Pharma EMEA is celebrating its 10 ... through the historic merger of Japanese pharmaceutical companies Yamanouchi ... committed to turning science into value for patients through ...
Breaking Medicine Technology:Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference 2Organovo Holdings, Inc. To Present at Jeffries 2015 Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 2RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 3RXi Pharmaceuticals to Present at the Jefferies 2015 Global Healthcare Conference 4Astellas Pharma EMEA Celebrates Its 10th Anniversary 2Astellas Pharma EMEA Celebrates Its 10th Anniversary 3Astellas Pharma EMEA Celebrates Its 10th Anniversary 4
... symptoms of ADHD, DURHAM, N.C., Sept. 10 ... stress has been shown to significantly reduce,symptoms of ... phase 3 clinical trial conducted by Addrenex,Pharmaceuticals., ... achieved statistically,significant improvement over placebo in reducing an ...
... combination of micronutrients superior to, current ,AREDS, standard ... -, HOUSTON, Sept. 10 A landmark ... a patented,combination of antioxidants and micronutrients, enabled patients ... in the study,s,placebo arm, who received the "AREDS-type" ...
Cached Medicine Technology:Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD 2Addrenex Pharmaceuticals Announces Positive Phase III Clinical Results for Clonicel to Treat ADHD 3TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 2TOZAL(R) Nutritional Supplement Improves Vision in Common Form of Macular Degeneration 3
(Date:5/26/2015)... 26, 2015 Abington is pleased ... a physician practice with seven medical professionals, has ... eighth primary-care site in the United States to ... home by the National Committee for Quality Assurance. ... preventative and sick care – including routine gynecology ...
(Date:5/26/2015)... CA (PRWEB) May 26, 2015 Two ... recently joined Dr. Marissa Pei on a ... conversation focusing on addiction. Aired on KCAA AM 1050, ... Deena Duncan, marriage and family therapist, as they discuss ... estimated to affect more than 23.5 million Americans. The ...
(Date:5/26/2015)... May 26, 2015 CIO Review has chosen ... Promising Pharma and Life Sciences Technology Solution Providers. The positioning ... 11 compliant solution which is applicable across the entire security ... necessary for broad adoption. , “SIGNiX has been on ... the Pharma and Life Sciences Technology space, and we are ...
(Date:5/26/2015)... National Prevention Week , National Prevention Week is ... by the Substance Abuse and Mental Health Services Administration ... action about, substance abuse as well as mental health ... to join in promoting prevention strategies, in educating other ... building community partnerships. , The Voice of One, the ...
(Date:5/26/2015)... Scientists at the University of Pennsylvania ... advanced mesothelioma patients benefit from immunotherapy; surgery may be ... on the new research. Click here to read ... thoracic surgery and pulmonology theorized that, because large mesothelioma ... attack, immunotherapy drugs might work better if the tumor ...
Breaking Medicine News(10 mins):Health News:Family Medicine, Geriatrics and Wellness Joins Abington Health Physicians 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 2Health News:Anaheim Lighthouse Staff Joined Dr. Marissa Pei’s in a Conversation on Drug and Alcohol Addiction 3Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 2Health News:CIO Review Selects SIGNiX as a 20 Most Promising Pharma and Life Sciences Technology Solution Provider in 2015 3Health News:Narconon Arrowhead Takes Part in National Prevention Week 2Health News:Narconon Arrowhead Takes Part in National Prevention Week 3Health News:Researchers Say Surgery May Restore Effectiveness of Immunotherapy for Mesothelioma, According to Surviving Mesothelioma 2
... Nov. 12 Governor Jennifer M.,Granholm, Attorney General ... Barrett today kicked off the 4th Annual "Support ... raises funds to,support Michigan soldiers, sailors, and Marines ... benefit the Bob Woodruff Family,Fund founded by Michigan ...
... personalized portal for referring ... ... AMCS ),a leader in radiology and medical image and information management,solutions, ... that can help imaging businesses grow by attracting,referrals and securing referring ...
... eDiets.com,Inc. (Nasdaq: DIET ), leveraging the ... both consumers and businesses, today announced that it,has ... will report results for its third quarter ended ... on Wednesday, November 14, 2007 and,will host a ...
... may be tied to weight , , MONDAY, Nov. 12 (HealthDay ... health problems, new research suggests that fat men are twice ... than men of normal weight. , The research doesn,t confirm ... death from prostate cancer, and it,s not clear if losing ...
... researchers have developed a small molecule that can turn the ... death signal. The molecule mimics the activity of Smac, a ... cells. ,The researchers say their findings suggest that Smac-mimetic ... and other cancers. Such therapy may be less toxic to ...
... Health releases nationwide eValue8,findings, SCOTTSDALE, Ariz., ... report of health plan performance released today ... (NBCH), health plans could do a,better job ... enabling,improvements in patient safety, care coordination, consumer ...
Cached Medicine News:Health News:Governor Granholm, Attorney General Cox, & Michigan Chamber Kick Off 4th Annual 'Support MI Troops' Fundraising Drive Proceeds to Benefit the Bob Woodruff Family Fund 2Health News:AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow 2Health News:AMICAS Launches Vision Reach 2.0, a Tool to Help Radiology Businesses Grow 3Health News:eDiets.com(R) Updates Timing of Third Quarter 2007 Earnings Conference Call 2Health News:Obesity Linked to Prostate Cancer Death Rates 2Health News:Obesity Linked to Prostate Cancer Death Rates 3Health News:Smac-ing lung cancer to death 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 2Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 3Health News:National Survey Finds Employers are Challenging Health Plans to Better Use Resources to Prevent Illness and Improve Patient Safety 4
10 L, Bulk Recommended for 2, 5 and 10 L pipettes....
10 L, Bulk Recommended for 2, 5, 10 L pipettes....
... Theken eDISC is a revolutionary advancement in ... assess and manage their patients. The eDISC's ... the eDISC from 1st and 2nd generation ... loads of the lumbar spine, the eDISC ...
... Resistant Tips offer a safe alternative to ... designed for applications such as PCR(a), pipetting ... ART Tips are excellent for tissue culture, ... ART Tips prevent aerosol contaminants and liquids ...
Medicine Products: